SHP-77

SHP-77 (Lung Cancer CDX Model) 

The SHP-77 line was derived from a patient with small cell lung carcinoma (SCLC). It displays neuroendocrine features characteristic of this aggressive cancer subtype. SHP-77 is widely used in preclinical SCLC research. Its stable growth provides reproducibility in oncology pipelines. 

Key Features: 

• Derived from small cell lung carcinoma. 

• Neuroendocrine morphology. 

• Highly tumorigenic in xenografts. 

• Represents aggressive SCLC biology. 

Applications: 
SHP-77 is used in studies of cytotoxic and targeted therapies for SCLC. Researchers apply it in biomarker discovery and resistance mechanism research. It is frequently used in neuroendocrine tumor biology studies. Its reproducibility ensures consistency in translational pipelines.